Slovenia JAZMP · August 26, 2026

Rybelsus (semaglutide): risk of medication errors with new formulation

Original title: Rybelsus (semaglutid): tveganje za napake pri jemanju nove formulacije zdravila

Risk of medication errors identified with new Rybelsus formulation launching in Slovenia in early September.

Low obligation Product class Pharmaceuticals Slovenia Pharmacovigilance

Pri zdravilu za sladkorno bolezen Rybelsus (semaglutid) obstaja tveganje za napake pri uporabi zaradi uvedbe nove formulacije zdravila, ki bo na slovenskem trgu na voljo v prvi polovici septembra. Nova […]

Read the official source ↗

Published by Slovenia JAZMP. HealthSignal links to the original document; the summary above is extracted from the source text.